These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1383 related items for PubMed ID: 26573228

  • 1. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
    Ceccarelli S, Panera N, Mina M, Gnani D, De Stefanis C, Crudele A, Rychlicki C, Petrini S, Bruscalupi G, Agostinelli L, Stronati L, Cucchiara S, Musso G, Furlanello C, Svegliati-Baroni G, Nobili V, Alisi A.
    Oncotarget; 2015 Dec 08; 6(39):41434-52. PubMed ID: 26573228
    [Abstract] [Full Text] [Related]

  • 2. Interleukin-22 ameliorates liver fibrogenesis by attenuating hepatic stellate cell activation and downregulating the levels of inflammatory cytokines.
    Lu DH, Guo XY, Qin SY, Luo W, Huang XL, Chen M, Wang JX, Ma SJ, Yang XW, Jiang HX.
    World J Gastroenterol; 2015 Feb 07; 21(5):1531-45. PubMed ID: 25663772
    [Abstract] [Full Text] [Related]

  • 3. Caffeic acid phenethyl ester attenuates pro-inflammatory and fibrogenic phenotypes of LPS-stimulated hepatic stellate cells through the inhibition of NF-κB signaling.
    Zhao WX, Wang L, Yang JL, Li LZ, Xu WM, Li T.
    Int J Mol Med; 2014 Mar 07; 33(3):687-94. PubMed ID: 24378685
    [Abstract] [Full Text] [Related]

  • 4. Adipose tissue-derived stem cells prevent fibrosis in murine steatohepatitis by suppressing IL-17-mediated inflammation.
    Yamato M, Sakai Y, Mochida H, Kawaguchi K, Takamura M, Usui S, Seki A, Mizukoshi E, Yamashita T, Yamashita T, Ishida K, Nasti A, Tuyen HTB, Komura T, Yoshida K, Wada T, Honda M, Kaneko S.
    J Gastroenterol Hepatol; 2019 Aug 07; 34(8):1432-1440. PubMed ID: 30828861
    [Abstract] [Full Text] [Related]

  • 5. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.
    Dongiovanni P, Meroni M, Baselli GA, Bassani GA, Rametta R, Pietrelli A, Maggioni M, Facciotti F, Trunzo V, Badiali S, Fargion S, Gatti S, Valenti L.
    Clin Sci (Lond); 2017 Jun 01; 131(12):1301-1315. PubMed ID: 28468951
    [Abstract] [Full Text] [Related]

  • 6. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
    Chong LW, Hsu YC, Lee TF, Lin Y, Chiu YT, Yang KC, Wu JC, Huang YT.
    BMC Gastroenterol; 2015 Feb 15; 15():22. PubMed ID: 25886887
    [Abstract] [Full Text] [Related]

  • 7. Activin-A causes Hepatic stellate cell activation via the induction of TNFα and TGFβ in Kupffer cells.
    Kiagiadaki F, Kampa M, Voumvouraki A, Castanas E, Kouroumalis E, Notas G.
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar 15; 1864(3):891-899. PubMed ID: 29287776
    [Abstract] [Full Text] [Related]

  • 8. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M, Bukong TN, Csak T, Saha B, Park JK, Ambade A, Kodys K, Szabo G.
    J Transl Med; 2015 Jun 16; 13():193. PubMed ID: 26077675
    [Abstract] [Full Text] [Related]

  • 9. Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells.
    Kim M, Yang SG, Kim JM, Lee JW, Kim YS, Lee JI.
    Int J Mol Med; 2012 Sep 16; 30(3):473-9. PubMed ID: 22710359
    [Abstract] [Full Text] [Related]

  • 10. Cell-specific PPARγ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells.
    Morán-Salvador E, Titos E, Rius B, González-Périz A, García-Alonso V, López-Vicario C, Miquel R, Barak Y, Arroyo V, Clària J.
    J Hepatol; 2013 Nov 16; 59(5):1045-53. PubMed ID: 23831119
    [Abstract] [Full Text] [Related]

  • 11. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    Bates J, Vijayakumar A, Ghoshal S, Marchand B, Yi S, Kornyeyev D, Zagorska A, Hollenback D, Walker K, Liu K, Pendem S, Newstrom D, Brockett R, Mikaelian I, Kusam S, Ramirez R, Lopez D, Li L, Fuchs BC, Breckenridge DG.
    J Hepatol; 2020 Oct 16; 73(4):896-905. PubMed ID: 32376414
    [Abstract] [Full Text] [Related]

  • 12. A retinoic acid receptor β2 agonist reduces hepatic stellate cell activation in nonalcoholic fatty liver disease.
    Trasino SE, Tang XH, Jessurun J, Gudas LJ.
    J Mol Med (Berl); 2016 Oct 16; 94(10):1143-1151. PubMed ID: 27271256
    [Abstract] [Full Text] [Related]

  • 13. Assessing the combined impact of fatty liver-induced TGF-β1 and LPS-activated macrophages in fibrosis through a novel 3D serial section methodology.
    Ishiyama S, Hayatsu M, Toriumi T, Tsuda H, Watanabe K, Kasai H, Kishigami S, Mochizuki K, Mikami Y.
    Sci Rep; 2024 May 18; 14(1):11404. PubMed ID: 38762616
    [Abstract] [Full Text] [Related]

  • 14. GDF11 induces mild hepatic fibrosis independent of metabolic health.
    Frohlich J, Kovacovicova K, Mazza T, Emma MR, Cabibi D, Foti M, Sobolewski C, Oben JA, Peyrou M, Villarroya F, Soresi M, Rezzani R, Cervello M, Bonomini F, Alisi A, Vinciguerra M.
    Aging (Albany NY); 2020 Oct 28; 12(20):20024-20046. PubMed ID: 33126224
    [Abstract] [Full Text] [Related]

  • 15. TMEM100 mediates inflammatory cytokines secretion in hepatic stellate cells and its mechanism research.
    Pan LX, Li LY, Zhou H, Cheng SQ, Liu YM, Lian PP, Li L, Wang LL, Rong SJ, Shen CP, Li J, Xu T.
    Toxicol Lett; 2019 Dec 15; 317():82-91. PubMed ID: 30639579
    [Abstract] [Full Text] [Related]

  • 16. A20 Attenuates Liver Fibrosis in NAFLD and Inhibits Inflammation Responses.
    Wang X, Ai L, Xu Q, Wu C, Chen Z, Su D, Jiang X, Fan Z.
    Inflammation; 2017 Jun 15; 40(3):840-848. PubMed ID: 28251449
    [Abstract] [Full Text] [Related]

  • 17. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
    Romualdo GR, Da Silva TC, de Albuquerque Landi MF, Morais JÁ, Barbisan LF, Vinken M, Oliveira CP, Cogliati B.
    Environ Toxicol; 2021 Feb 15; 36(2):168-176. PubMed ID: 32918399
    [Abstract] [Full Text] [Related]

  • 18. Transcriptional repression of SIRT1 by protein inhibitor of activated STAT 4 (PIAS4) in hepatic stellate cells contributes to liver fibrosis.
    Sun L, Fan Z, Chen J, Tian W, Li M, Xu H, Wu X, Shao J, Bian Y, Fang M, Xu Y.
    Sci Rep; 2016 Jun 21; 6():28432. PubMed ID: 27323886
    [Abstract] [Full Text] [Related]

  • 19. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation.
    Yao J, Zhou CS, Ma X, Fu BQ, Tao LS, Chen M, Xu YP.
    World J Gastroenterol; 2014 Oct 21; 20(39):14430-41. PubMed ID: 25339829
    [Abstract] [Full Text] [Related]

  • 20. Astaxanthin prevents TGFβ1-induced pro-fibrogenic gene expression by inhibiting Smad3 activation in hepatic stellate cells.
    Yang Y, Kim B, Park YK, Koo SI, Lee JY.
    Biochim Biophys Acta; 2015 Jan 21; 1850(1):178-85. PubMed ID: 25450180
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.